Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Identifieur interne : 001179 ( Main/Exploration ); précédent : 001178; suivant : 001180Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Auteurs : Dora Pinto [Suisse] ; Young-Jun Park [États-Unis] ; Martina Beltramello [Suisse] ; Alexandra C. Walls [États-Unis] ; M Alejandra Tortorici [États-Unis, France] ; Siro Bianchi [Suisse] ; Stefano Jaconi [Suisse] ; Katja Culap [Suisse] ; Fabrizia Zatta [Suisse] ; Anna De Marco [Suisse] ; Alessia Peter [Suisse] ; Barbara Guarino [Suisse] ; Roberto Spreafico [États-Unis] ; Elisabetta Cameroni [Suisse] ; James Brett Case [États-Unis] ; Rita E. Chen [États-Unis] ; Colin Havenar-Daughton [États-Unis] ; Gyorgy Snell [États-Unis] ; Amalio Telenti [États-Unis] ; Herbert W. Virgin [États-Unis] ; Antonio Lanzavecchia [Suisse] ; Michael S. Diamond [États-Unis] ; Katja Fink [Suisse] ; David Veesler [États-Unis] ; Davide Corti [Suisse]Source :
- Nature [ 1476-4687 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Anticorps antiviraux (composition chimique), Anticorps antiviraux (immunologie), Anticorps antiviraux (pharmacologie), Anticorps monoclonaux (composition chimique), Anticorps monoclonaux (immunologie), Anticorps monoclonaux (pharmacologie), Anticorps neutralisants (composition chimique), Anticorps neutralisants (immunologie), Anticorps neutralisants (pharmacologie), Betacoronavirus (composition chimique), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Cellules HEK293 (MeSH), Cellules Vero (MeSH), Cellules tueuses naturelles (effets des médicaments et des substances chimiques), Cellules tueuses naturelles (immunologie), Cryomicroscopie électronique (MeSH), Cytotoxicité à médiation cellulaire dépendante des anticorps (effets des médicaments et des substances chimiques), Cytotoxicité à médiation cellulaire dépendante des anticorps (immunologie), Déterminants antigéniques des lymphocytes B (composition chimique), Déterminants antigéniques des lymphocytes B (immunologie), Fragments Fab d'immunoglobuline (composition chimique), Fragments Fab d'immunoglobuline (immunologie), Fragments Fab d'immunoglobuline (pharmacologie), Glycoprotéine de spicule des coronavirus (composition chimique), Glycoprotéine de spicule des coronavirus (immunologie), Humains (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (thérapie), Infections à coronavirus (virologie), Lymphocytes B (immunologie), Modèles moléculaires (MeSH), Mémoire immunologique (immunologie), Pandémies (prévention et contrôle), Peptidyl-Dipeptidase A (composition chimique), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (immunologie), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (thérapie), Pneumopathie virale (virologie), Réactions croisées (effets des médicaments et des substances chimiques), Réactions croisées (immunologie), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Tests de neutralisation (MeSH), Virus du SRAS (composition chimique), Virus du SRAS (effets des médicaments et des substances chimiques), Virus du SRAS (immunologie), Échappement immunitaire (immunologie).
- MESH :
- composition chimique : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants, Betacoronavirus, Déterminants antigéniques des lymphocytes B, Fragments Fab d'immunoglobuline, Glycoprotéine de spicule des coronavirus, Peptidyl-Dipeptidase A, Virus du SRAS.
- effets des médicaments et des substances chimiques : Betacoronavirus, Cellules tueuses naturelles, Cytotoxicité à médiation cellulaire dépendante des anticorps, Réactions croisées, Virus du SRAS.
- immunologie : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants, Betacoronavirus, Cellules tueuses naturelles, Cytotoxicité à médiation cellulaire dépendante des anticorps, Déterminants antigéniques des lymphocytes B, Fragments Fab d'immunoglobuline, Glycoprotéine de spicule des coronavirus, Infections à coronavirus, Lymphocytes B, Mémoire immunologique, Pneumopathie virale, Réactions croisées, Syndrome respiratoire aigu sévère, Virus du SRAS, Échappement immunitaire.
- métabolisme : Peptidyl-Dipeptidase A.
- pharmacologie : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants, Fragments Fab d'immunoglobuline.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- virologie : Infections à coronavirus, Pneumopathie virale, Syndrome respiratoire aigu sévère.
- Animaux, Cellules HEK293, Cellules Vero, Cryomicroscopie électronique, Humains, Modèles moléculaires, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals (MeSH), Antibodies, Monoclonal (chemistry), Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (pharmacology), Antibodies, Neutralizing (chemistry), Antibodies, Neutralizing (immunology), Antibodies, Neutralizing (pharmacology), Antibodies, Viral (chemistry), Antibodies, Viral (immunology), Antibodies, Viral (pharmacology), Antibody-Dependent Cell Cytotoxicity (drug effects), Antibody-Dependent Cell Cytotoxicity (immunology), B-Lymphocytes (immunology), Betacoronavirus (chemistry), Betacoronavirus (drug effects), Betacoronavirus (immunology), Chlorocebus aethiops (MeSH), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (therapy), Coronavirus Infections (virology), Cross Reactions (drug effects), Cross Reactions (immunology), Cryoelectron Microscopy (MeSH), Epitopes, B-Lymphocyte (chemistry), Epitopes, B-Lymphocyte (immunology), HEK293 Cells (MeSH), Humans (MeSH), Immune Evasion (immunology), Immunoglobulin Fab Fragments (chemistry), Immunoglobulin Fab Fragments (immunology), Immunoglobulin Fab Fragments (pharmacology), Immunologic Memory (immunology), Killer Cells, Natural (drug effects), Killer Cells, Natural (immunology), Models, Molecular (MeSH), Neutralization Tests (MeSH), Pandemics (prevention & control), Peptidyl-Dipeptidase A (chemistry), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (immunology), Pneumonia, Viral (prevention & control), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), SARS Virus (chemistry), SARS Virus (drug effects), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus (chemistry), Spike Glycoprotein, Coronavirus (immunology), Vero Cells (MeSH).
- MESH :
- chemical , chemistry : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Epitopes, B-Lymphocyte, Immunoglobulin Fab Fragments, Peptidyl-Dipeptidase A, Spike Glycoprotein, Coronavirus.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Epitopes, B-Lymphocyte, Immunoglobulin Fab Fragments, Spike Glycoprotein, Coronavirus.
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Immunoglobulin Fab Fragments.
- chemistry : Betacoronavirus, SARS Virus.
- drug effects : Antibody-Dependent Cell Cytotoxicity, Betacoronavirus, Cross Reactions, Killer Cells, Natural, SARS Virus.
- immunology : Antibody-Dependent Cell Cytotoxicity, B-Lymphocytes, Betacoronavirus, Coronavirus Infections, Cross Reactions, Immune Evasion, Immunologic Memory, Killer Cells, Natural, Pneumonia, Viral, SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral, Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Cryoelectron Microscopy, HEK293 Cells, Humans, Models, Molecular, Neutralization Tests, Vero Cells.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.
DOI: 10.1038/s41586-020-2349-y
PubMed: 32422645
Affiliations:
- France, Suisse, États-Unis
- Californie, Missouri (État), Washington (État), Île-de-France
- Paris, Saint-Louis (Missouri), Seattle
- Université de Washington, École de médecine (Université Washington de Saint-Louis)
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.</title><author><name sortKey="Pinto, Dora" sort="Pinto, Dora" uniqKey="Pinto D" first="Dora" last="Pinto">Dora Pinto</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Park, Young Jun" sort="Park, Young Jun" uniqKey="Park Y" first="Young-Jun" last="Park">Young-Jun Park</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Beltramello, Martina" sort="Beltramello, Martina" uniqKey="Beltramello M" first="Martina" last="Beltramello">Martina Beltramello</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Walls, Alexandra C" sort="Walls, Alexandra C" uniqKey="Walls A" first="Alexandra C" last="Walls">Alexandra C. Walls</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Tortorici, M Alejandra" sort="Tortorici, M Alejandra" uniqKey="Tortorici M" first="M Alejandra" last="Tortorici">M Alejandra Tortorici</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bianchi, Siro" sort="Bianchi, Siro" uniqKey="Bianchi S" first="Siro" last="Bianchi">Siro Bianchi</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Jaconi, Stefano" sort="Jaconi, Stefano" uniqKey="Jaconi S" first="Stefano" last="Jaconi">Stefano Jaconi</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Culap, Katja" sort="Culap, Katja" uniqKey="Culap K" first="Katja" last="Culap">Katja Culap</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Zatta, Fabrizia" sort="Zatta, Fabrizia" uniqKey="Zatta F" first="Fabrizia" last="Zatta">Fabrizia Zatta</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="De Marco, Anna" sort="De Marco, Anna" uniqKey="De Marco A" first="Anna" last="De Marco">Anna De Marco</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Peter, Alessia" sort="Peter, Alessia" uniqKey="Peter A" first="Alessia" last="Peter">Alessia Peter</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Guarino, Barbara" sort="Guarino, Barbara" uniqKey="Guarino B" first="Barbara" last="Guarino">Barbara Guarino</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Spreafico, Roberto" sort="Spreafico, Roberto" uniqKey="Spreafico R" first="Roberto" last="Spreafico">Roberto Spreafico</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Case, James Brett" sort="Case, James Brett" uniqKey="Case J" first="James Brett" last="Case">James Brett Case</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Chen, Rita E" sort="Chen, Rita E" uniqKey="Chen R" first="Rita E" last="Chen">Rita E. Chen</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Havenar Daughton, Colin" sort="Havenar Daughton, Colin" uniqKey="Havenar Daughton C" first="Colin" last="Havenar-Daughton">Colin Havenar-Daughton</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Snell, Gyorgy" sort="Snell, Gyorgy" uniqKey="Snell G" first="Gyorgy" last="Snell">Gyorgy Snell</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Telenti, Amalio" sort="Telenti, Amalio" uniqKey="Telenti A" first="Amalio" last="Telenti">Amalio Telenti</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Virgin, Herbert W" sort="Virgin, Herbert W" uniqKey="Virgin H" first="Herbert W" last="Virgin">Herbert W. Virgin</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S" last="Diamond">Michael S. Diamond</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Fink, Katja" sort="Fink, Katja" uniqKey="Fink K" first="Katja" last="Fink">Katja Fink</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Veesler, David" sort="Veesler, David" uniqKey="Veesler D" first="David" last="Veesler">David Veesler</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32422645</idno><idno type="pmid">32422645</idno><idno type="doi">10.1038/s41586-020-2349-y</idno><idno type="wicri:Area/Main/Corpus">001232</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001232</idno><idno type="wicri:Area/Main/Curation">001232</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001232</idno><idno type="wicri:Area/Main/Exploration">001232</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.</title><author><name sortKey="Pinto, Dora" sort="Pinto, Dora" uniqKey="Pinto D" first="Dora" last="Pinto">Dora Pinto</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Park, Young Jun" sort="Park, Young Jun" uniqKey="Park Y" first="Young-Jun" last="Park">Young-Jun Park</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Beltramello, Martina" sort="Beltramello, Martina" uniqKey="Beltramello M" first="Martina" last="Beltramello">Martina Beltramello</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Walls, Alexandra C" sort="Walls, Alexandra C" uniqKey="Walls A" first="Alexandra C" last="Walls">Alexandra C. Walls</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Tortorici, M Alejandra" sort="Tortorici, M Alejandra" uniqKey="Tortorici M" first="M Alejandra" last="Tortorici">M Alejandra Tortorici</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Bianchi, Siro" sort="Bianchi, Siro" uniqKey="Bianchi S" first="Siro" last="Bianchi">Siro Bianchi</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Jaconi, Stefano" sort="Jaconi, Stefano" uniqKey="Jaconi S" first="Stefano" last="Jaconi">Stefano Jaconi</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Culap, Katja" sort="Culap, Katja" uniqKey="Culap K" first="Katja" last="Culap">Katja Culap</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Zatta, Fabrizia" sort="Zatta, Fabrizia" uniqKey="Zatta F" first="Fabrizia" last="Zatta">Fabrizia Zatta</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="De Marco, Anna" sort="De Marco, Anna" uniqKey="De Marco A" first="Anna" last="De Marco">Anna De Marco</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Peter, Alessia" sort="Peter, Alessia" uniqKey="Peter A" first="Alessia" last="Peter">Alessia Peter</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Guarino, Barbara" sort="Guarino, Barbara" uniqKey="Guarino B" first="Barbara" last="Guarino">Barbara Guarino</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Spreafico, Roberto" sort="Spreafico, Roberto" uniqKey="Spreafico R" first="Roberto" last="Spreafico">Roberto Spreafico</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Case, James Brett" sort="Case, James Brett" uniqKey="Case J" first="James Brett" last="Case">James Brett Case</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Chen, Rita E" sort="Chen, Rita E" uniqKey="Chen R" first="Rita E" last="Chen">Rita E. Chen</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Havenar Daughton, Colin" sort="Havenar Daughton, Colin" uniqKey="Havenar Daughton C" first="Colin" last="Havenar-Daughton">Colin Havenar-Daughton</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Snell, Gyorgy" sort="Snell, Gyorgy" uniqKey="Snell G" first="Gyorgy" last="Snell">Gyorgy Snell</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Telenti, Amalio" sort="Telenti, Amalio" uniqKey="Telenti A" first="Amalio" last="Telenti">Amalio Telenti</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Virgin, Herbert W" sort="Virgin, Herbert W" uniqKey="Virgin H" first="Herbert W" last="Virgin">Herbert W. Virgin</name><affiliation wicri:level="2"><nlm:affiliation>Vir Biotechnology, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vir Biotechnology, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S" last="Diamond">Michael S. Diamond</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName></affiliation></author><author><name sortKey="Fink, Katja" sort="Fink, Katja" uniqKey="Fink K" first="Katja" last="Fink">Katja Fink</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Veesler, David" sort="Veesler, David" uniqKey="Veesler D" first="David" last="Veesler">David Veesler</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biochemistry, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, Vir Biotechnology, Bellinzona</wicri:regionArea><wicri:noRegion>Bellinzona</wicri:noRegion></affiliation></author></analytic><series><title level="j">Nature</title><idno type="eISSN">1476-4687</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antibodies, Monoclonal (chemistry)</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibodies, Neutralizing (chemistry)</term><term>Antibodies, Neutralizing (immunology)</term><term>Antibodies, Neutralizing (pharmacology)</term><term>Antibodies, Viral (chemistry)</term><term>Antibodies, Viral (immunology)</term><term>Antibodies, Viral (pharmacology)</term><term>Antibody-Dependent Cell Cytotoxicity (drug effects)</term><term>Antibody-Dependent Cell Cytotoxicity (immunology)</term><term>B-Lymphocytes (immunology)</term><term>Betacoronavirus (chemistry)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (immunology)</term><term>Chlorocebus aethiops (MeSH)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Cross Reactions (drug effects)</term><term>Cross Reactions (immunology)</term><term>Cryoelectron Microscopy (MeSH)</term><term>Epitopes, B-Lymphocyte (chemistry)</term><term>Epitopes, B-Lymphocyte (immunology)</term><term>HEK293 Cells (MeSH)</term><term>Humans (MeSH)</term><term>Immune Evasion (immunology)</term><term>Immunoglobulin Fab Fragments (chemistry)</term><term>Immunoglobulin Fab Fragments (immunology)</term><term>Immunoglobulin Fab Fragments (pharmacology)</term><term>Immunologic Memory (immunology)</term><term>Killer Cells, Natural (drug effects)</term><term>Killer Cells, Natural (immunology)</term><term>Models, Molecular (MeSH)</term><term>Neutralization Tests (MeSH)</term><term>Pandemics (prevention & control)</term><term>Peptidyl-Dipeptidase A (chemistry)</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (prevention & control)</term><term>Pneumonia, Viral (therapy)</term><term>Pneumonia, Viral (virology)</term><term>SARS Virus (chemistry)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus (chemistry)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term><term>Vero Cells (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Anticorps antiviraux (composition chimique)</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (pharmacologie)</term><term>Anticorps monoclonaux (composition chimique)</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (pharmacologie)</term><term>Anticorps neutralisants (composition chimique)</term><term>Anticorps neutralisants (immunologie)</term><term>Anticorps neutralisants (pharmacologie)</term><term>Betacoronavirus (composition chimique)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Betacoronavirus (immunologie)</term><term>Cellules HEK293 (MeSH)</term><term>Cellules Vero (MeSH)</term><term>Cellules tueuses naturelles (effets des médicaments et des substances chimiques)</term><term>Cellules tueuses naturelles (immunologie)</term><term>Cryomicroscopie électronique (MeSH)</term><term>Cytotoxicité à médiation cellulaire dépendante des anticorps (effets des médicaments et des substances chimiques)</term><term>Cytotoxicité à médiation cellulaire dépendante des anticorps (immunologie)</term><term>Déterminants antigéniques des lymphocytes B (composition chimique)</term><term>Déterminants antigéniques des lymphocytes B (immunologie)</term><term>Fragments Fab d'immunoglobuline (composition chimique)</term><term>Fragments Fab d'immunoglobuline (immunologie)</term><term>Fragments Fab d'immunoglobuline (pharmacologie)</term><term>Glycoprotéine de spicule des coronavirus (composition chimique)</term><term>Glycoprotéine de spicule des coronavirus (immunologie)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Infections à coronavirus (thérapie)</term><term>Infections à coronavirus (virologie)</term><term>Lymphocytes B (immunologie)</term><term>Modèles moléculaires (MeSH)</term><term>Mémoire immunologique (immunologie)</term><term>Pandémies (prévention et contrôle)</term><term>Peptidyl-Dipeptidase A (composition chimique)</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (prévention et contrôle)</term><term>Pneumopathie virale (thérapie)</term><term>Pneumopathie virale (virologie)</term><term>Réactions croisées (effets des médicaments et des substances chimiques)</term><term>Réactions croisées (immunologie)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation (MeSH)</term><term>Virus du SRAS (composition chimique)</term><term>Virus du SRAS (effets des médicaments et des substances chimiques)</term><term>Virus du SRAS (immunologie)</term><term>Échappement immunitaire (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Epitopes, B-Lymphocyte</term><term>Immunoglobulin Fab Fragments</term><term>Peptidyl-Dipeptidase A</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Epitopes, B-Lymphocyte</term><term>Immunoglobulin Fab Fragments</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Immunoglobulin Fab Fragments</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Betacoronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Anticorps neutralisants</term><term>Betacoronavirus</term><term>Déterminants antigéniques des lymphocytes B</term><term>Fragments Fab d'immunoglobuline</term><term>Glycoprotéine de spicule des coronavirus</term><term>Peptidyl-Dipeptidase A</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Antibody-Dependent Cell Cytotoxicity</term><term>Betacoronavirus</term><term>Cross Reactions</term><term>Killer Cells, Natural</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term><term>Cellules tueuses naturelles</term><term>Cytotoxicité à médiation cellulaire dépendante des anticorps</term><term>Réactions croisées</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Anticorps neutralisants</term><term>Betacoronavirus</term><term>Cellules tueuses naturelles</term><term>Cytotoxicité à médiation cellulaire dépendante des anticorps</term><term>Déterminants antigéniques des lymphocytes B</term><term>Fragments Fab d'immunoglobuline</term><term>Glycoprotéine de spicule des coronavirus</term><term>Infections à coronavirus</term><term>Lymphocytes B</term><term>Mémoire immunologique</term><term>Pneumopathie virale</term><term>Réactions croisées</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term><term>Échappement immunitaire</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody-Dependent Cell Cytotoxicity</term><term>B-Lymphocytes</term><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Cross Reactions</term><term>Immune Evasion</term><term>Immunologic Memory</term><term>Killer Cells, Natural</term><term>Pneumonia, Viral</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Anticorps neutralisants</term><term>Fragments Fab d'immunoglobuline</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Cryoelectron Microscopy</term><term>HEK293 Cells</term><term>Humans</term><term>Models, Molecular</term><term>Neutralization Tests</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules HEK293</term><term>Cellules Vero</term><term>Cryomicroscopie électronique</term><term>Humains</term><term>Modèles moléculaires</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020<sup>1,2</sup>. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32422645</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>583</Volume><Issue>7815</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.</ArticleTitle><Pagination><MedlinePgn>290-295</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-020-2349-y</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020<sup>1,2</sup>. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Dora</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Young-Jun</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltramello</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walls</LastName><ForeName>Alexandra C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortorici</LastName><ForeName>M Alejandra</ForeName><Initials>MA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-2260-2577</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Siro</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5100-8905</Identifier><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaconi</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culap</LastName><ForeName>Katja</ForeName><Initials>K</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0956-0018</Identifier><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zatta</LastName><ForeName>Fabrizia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marco</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peter</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarino</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spreafico</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cameroni</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Case</LastName><ForeName>James Brett</ForeName><Initials>JB</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7331-5511</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rita E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havenar-Daughton</LastName><ForeName>Colin</ForeName><Initials>C</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-2880-3927</Identifier><AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snell</LastName><ForeName>Gyorgy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telenti</LastName><ForeName>Amalio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virgin</LastName><ForeName>Herbert W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzavecchia</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veesler</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-6019-8675</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Davide</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5797-1364</Identifier><AffiliationInfo><Affiliation>Humabs BioMed SA, Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM120553</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN272201700059C</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75N93019C00062</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018985">Epitopes, B-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2020 Jul;583(7815):203-204</RefSource><PMID Version="1">32623442</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000920" MajorTopicYN="N">Antibody-Dependent Cell Cytotoxicity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018985" MajorTopicYN="N">Epitopes, B-Lymphocyte</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007140" MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32422645</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId><ArticleId IdType="pii">10.1038/s41586-020-2349-y</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>Missouri (État)</li><li>Washington (État)</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Saint-Louis (Missouri)</li><li>Seattle</li></settlement><orgName><li>Université de Washington</li><li>École de médecine (Université Washington de Saint-Louis)</li></orgName></list><tree><country name="Suisse"><noRegion><name sortKey="Pinto, Dora" sort="Pinto, Dora" uniqKey="Pinto D" first="Dora" last="Pinto">Dora Pinto</name></noRegion><name sortKey="Beltramello, Martina" sort="Beltramello, Martina" uniqKey="Beltramello M" first="Martina" last="Beltramello">Martina Beltramello</name><name sortKey="Bianchi, Siro" sort="Bianchi, Siro" uniqKey="Bianchi S" first="Siro" last="Bianchi">Siro Bianchi</name><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><name sortKey="Culap, Katja" sort="Culap, Katja" uniqKey="Culap K" first="Katja" last="Culap">Katja Culap</name><name sortKey="De Marco, Anna" sort="De Marco, Anna" uniqKey="De Marco A" first="Anna" last="De Marco">Anna De Marco</name><name sortKey="Fink, Katja" sort="Fink, Katja" uniqKey="Fink K" first="Katja" last="Fink">Katja Fink</name><name sortKey="Guarino, Barbara" sort="Guarino, Barbara" uniqKey="Guarino B" first="Barbara" last="Guarino">Barbara Guarino</name><name sortKey="Jaconi, Stefano" sort="Jaconi, Stefano" uniqKey="Jaconi S" first="Stefano" last="Jaconi">Stefano Jaconi</name><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><name sortKey="Peter, Alessia" sort="Peter, Alessia" uniqKey="Peter A" first="Alessia" last="Peter">Alessia Peter</name><name sortKey="Zatta, Fabrizia" sort="Zatta, Fabrizia" uniqKey="Zatta F" first="Fabrizia" last="Zatta">Fabrizia Zatta</name></country><country name="États-Unis"><region name="Washington (État)"><name sortKey="Park, Young Jun" sort="Park, Young Jun" uniqKey="Park Y" first="Young-Jun" last="Park">Young-Jun Park</name></region><name sortKey="Case, James Brett" sort="Case, James Brett" uniqKey="Case J" first="James Brett" last="Case">James Brett Case</name><name sortKey="Chen, Rita E" sort="Chen, Rita E" uniqKey="Chen R" first="Rita E" last="Chen">Rita E. Chen</name><name sortKey="Chen, Rita E" sort="Chen, Rita E" uniqKey="Chen R" first="Rita E" last="Chen">Rita E. Chen</name><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S" last="Diamond">Michael S. Diamond</name><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S" last="Diamond">Michael S. Diamond</name><name sortKey="Diamond, Michael S" sort="Diamond, Michael S" uniqKey="Diamond M" first="Michael S" last="Diamond">Michael S. Diamond</name><name sortKey="Havenar Daughton, Colin" sort="Havenar Daughton, Colin" uniqKey="Havenar Daughton C" first="Colin" last="Havenar-Daughton">Colin Havenar-Daughton</name><name sortKey="Snell, Gyorgy" sort="Snell, Gyorgy" uniqKey="Snell G" first="Gyorgy" last="Snell">Gyorgy Snell</name><name sortKey="Spreafico, Roberto" sort="Spreafico, Roberto" uniqKey="Spreafico R" first="Roberto" last="Spreafico">Roberto Spreafico</name><name sortKey="Telenti, Amalio" sort="Telenti, Amalio" uniqKey="Telenti A" first="Amalio" last="Telenti">Amalio Telenti</name><name sortKey="Tortorici, M Alejandra" sort="Tortorici, M Alejandra" uniqKey="Tortorici M" first="M Alejandra" last="Tortorici">M Alejandra Tortorici</name><name sortKey="Veesler, David" sort="Veesler, David" uniqKey="Veesler D" first="David" last="Veesler">David Veesler</name><name sortKey="Virgin, Herbert W" sort="Virgin, Herbert W" uniqKey="Virgin H" first="Herbert W" last="Virgin">Herbert W. Virgin</name><name sortKey="Walls, Alexandra C" sort="Walls, Alexandra C" uniqKey="Walls A" first="Alexandra C" last="Walls">Alexandra C. Walls</name></country><country name="France"><region name="Île-de-France"><name sortKey="Tortorici, M Alejandra" sort="Tortorici, M Alejandra" uniqKey="Tortorici M" first="M Alejandra" last="Tortorici">M Alejandra Tortorici</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001179 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001179 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32422645
|texte= Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32422645" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |